| Q1 2024 |
52 |
$674M |
+$59.4M |
-$24.5M |
+$34.9M |
AGO, MRK, C, BP, GSKXXXX, BMY |
13F-HR |
5/15/2024, 02:14 PM |
| Q4 2023 |
42 |
$635M |
+$7M |
-$19.4M |
-$12.4M |
AGO, MRK, NYCB, C, BP, GSKXXXX |
13F-HR |
2/13/2024, 10:33 AM |
| Q3 2023 |
42 |
$641M |
+$3.63M |
-$13.4M |
-$9.74M |
NYCB, BP, MRK, AGO, PTEN, C |
13F-HR |
11/13/2023, 04:42 PM |
| Q2 2023 |
42 |
$682M |
+$2.39M |
-$23.6M |
-$21.2M |
MRK, NYCB, BP, BMY, AGO, C |
13F-HR |
8/9/2023, 02:59 PM |
| Q1 2023 |
45 |
$695M |
+$8.08M |
-$27M |
-$18.9M |
BP, MRK, BMY, NYCB, AGO, C |
13F-HR |
5/12/2023, 10:36 AM |
| Q4 2022 |
45 |
$760M |
+$3.98M |
-$8.69M |
-$4.72M |
AGO, MRK, BP, PTEN, BMY, MBI |
13F-HR |
2/15/2023, 09:56 AM |
| Q3 2022 |
45 |
$642M |
+$14.2M |
-$13M |
+$1.19M |
BMY, BP, AGO, MRK, PTEN, NYCB |
13F-HR |
11/15/2022, 09:02 AM |
| Q2 2022 |
45 |
$743M |
+$21.1M |
-$17.5M |
+$3.63M |
PTEN, AGO, BMY, MRK, BP, GSKXXXX |
13F-HR |
8/10/2022, 12:36 PM |
| Q1 2022 |
46 |
$788M |
+$142M |
-$14.5M |
+$127M |
PTEN, AGO, MBI, BMY, BP, GSKXXXX |
13F-HR |
5/2/2022, 02:12 PM |
| Q4 2021 |
43 |
$728M |
+$17.3M |
-$2.05M |
+$15.2M |
MBI, AGO, GSKXXXX, PFE, BP, NYCB |
13F-HR |
1/25/2022, 08:25 AM |
| Q3 2021 |
43 |
$710M |
+$22.1M |
-$6.84M |
+$15.3M |
AGO, MBI, BP, NYCB, PTEN, GSKXXXX |
13F-HR |
11/1/2021, 10:31 AM |
| Q2 2021 |
43 |
$698M |
+$26.9M |
-$48.3M |
-$21.4M |
AGO, BMY, PTEN, BP, MBI, NYCB |
13F-HR |
8/4/2021, 10:17 AM |
| Q1 2021 |
42 |
$646M |
+$5.5M |
-$59M |
-$53.5M |
AGO, NYCB, BMY, MBI, BP, GSKXXXX |
13F-HR |
5/7/2021, 02:09 PM |
| Q4 2020 |
42 |
$573M |
+$3.74M |
-$53.6M |
-$49.8M |
BMY, AGO, GSKXXXX, NYCB, VOXX, BP |
13F-HR |
2/11/2021, 09:45 AM |
| Q3 2020 |
42 |
$528M |
+$6.62M |
-$43.9M |
-$37.3M |
BMY, GSKXXXX, NYCB, AGO, BP, SEB |
13F-HR |
11/6/2020, 08:36 AM |
| Q2 2020 |
47 |
$592M |
+$18.2M |
-$25.2M |
-$7.02M |
GSKXXXX, BMY, NYCB, BP, AGO, SEB |
13F-HR |
8/3/2020, 02:43 PM |
| Q1 2020 |
48 |
$547M |
+$1.83M |
-$25.6M |
-$23.8M |
GSKXXXX, BMY, NYCB, BP, AGO, MBI |
13F-HR |
5/11/2020, 10:16 AM |
| Q4 2019 |
47 |
$825M |
+$2.07M |
-$114M |
-$112M |
AGO, GSKXXXX, BMY, NYCB, BP, SEB |
13F-HR |
1/27/2020, 12:41 PM |
| Q3 2019 |
48 |
$798M |
+$14.9M |
-$398M |
-$383M |
AGO, NYCB, GSKXXXX, BP, SEB, BMY |
RESTATEMENT |
11/5/2019, 09:40 AM |
| Q2 2019 |
44 |
$800M |
+$251M |
-$6.61M |
+$245M |
BP, AGO, GSKXXXX, SEB, NYCB, MBI |
13F-HR |
8/5/2019, 11:27 AM |
| Q1 2019 |
32 |
$640M |
+$25.2M |
-$43.7M |
-$18.5M |
BP, AGO, GSKXXXX, NYCB, BB, MBI |
13F-HR |
5/6/2019, 10:06 AM |
| Q4 2018 |
31 |
$555M |
+$7.99M |
-$12.5M |
-$4.47M |
BP, AGO, GSKXXXX, NYCB, MBI, BB |
13F-HR |
1/29/2019, 01:33 PM |
| Q3 2018 |
31 |
$651M |
+$14.8M |
-$16.9M |
-$2.16M |
BP, AGO, BB, GSKXXXX, MBI, NYCB |
13F-HR |
10/30/2018, 02:36 PM |
| Q2 2018 |
31 |
$628M |
+$12.4M |
-$16.6M |
-$4.18M |
BP, GSKXXXX, NYT, AGO, BB, MBI |
13F-HR |
8/6/2018, 10:09 AM |
| Q1 2018 |
31 |
$628M |
+$16M |
-$23.7M |
-$7.67M |
BP, NYT, BB, GSKXXXX, AGO, MBI |
13F-HR |
5/1/2018, 03:04 PM |
| Q4 2017 |
31 |
$637M |
+$16.7M |
-$18M |
-$1.29M |
BP, NYT, BB, GSKXXXX, AGO, SEB |
13F-HR |
1/25/2018, 01:34 PM |
| Q3 2017 |
34 |
$655M |
+$24.6M |
-$40.4M |
-$15.7M |
NYT, BP, BB, GSKXXXX, MBI, SEB |
RESTATEMENT |
11/7/2017, 11:21 AM |
| Q2 2017 |
34 |
$656M |
+$24.7M |
-$28.4M |
-$3.76M |
NYT, BP, GSKXXXX, BB, MBI, HOLX |
13F-HR |
8/8/2017, 11:52 AM |
| Q1 2017 |
35 |
$581M |
+$27.9M |
-$28.2M |
-$245K |
NYT, BP, GSKXXXX, HOLX, MBI, BB |
13F-HR |
5/8/2017, 01:58 PM |
| Q4 2016 |
35 |
$592M |
+$32.7M |
-$18.3M |
+$14.4M |
NYT, BP, HOLX, MBI, NYCB, SEB |
13F-HR |
1/31/2017, 01:23 PM |
| Q3 2016 |
35 |
$552M |
+$15.9M |
-$16.8M |
-$868K |
HOLX, BP, NYT, BB, MBI, NYCB |
13F-HR |
11/1/2016, 10:03 AM |
| Q2 2016 |
37 |
$517M |
+$11.6M |
-$29.2M |
-$17.5M |
NYT, BP, HOLX, PFE, NYCB, MBI |
13F-HR |
8/9/2016, 01:27 PM |
| Q1 2016 |
37 |
$534M |
+$9.21M |
-$19.7M |
-$10.5M |
NYT, HOLX, NYCB, PFE, MBI, BP |
13F-HR |
5/9/2016, 10:58 AM |
| Q4 2015 |
38 |
$560M |
+$9.66M |
-$6.83M |
+$2.83M |
NYT, HOLX, PFE, NYCB, BB, BP |
13F-HR |
2/8/2016, 09:02 AM |
| Q3 2015 |
38 |
$540M |
+$20.5M |
-$16.6M |
+$3.82M |
HOLX, PFE, NYCB, NYT, BP, MBI |
13F-HR |
11/9/2015, 11:11 AM |
| Q2 2015 |
40 |
$593M |
+$17.9M |
-$26.7M |
-$8.82M |
PFE, NYCB, NYT, HOLX, BP, SEB |
13F-HR |
7/28/2015, 10:12 AM |
| Q1 2015 |
42 |
$592M |
+$8.13M |
-$33.9M |
-$25.8M |
PFE, NYT, NYCB, HOLX, SEB, BP |
13F-HR |
5/6/2015, 09:33 AM |
| Q4 2014 |
44 |
$580M |
+$8.55M |
-$41.3M |
-$32.7M |
PFE, NYT, NYCB, SEB, BP, ORI |
13F-HR |
2/3/2015, 09:54 AM |
| Q3 2014 |
44 |
$615M |
+$3.7M |
-$38.8M |
-$35.1M |
PFE, NYCB, NYT, HOLX, BP, ORI |
13F-HR |
11/6/2014, 09:45 AM |
| Q2 2014 |
43 |
$687M |
+$67.8M |
-$28.9M |
+$38.9M |
NYT, PFE, NYCB, BP, HOLX, ORI |
13F-HR |
8/6/2014, 02:37 PM |
| Q1 2014 |
42 |
$701M |
+$93.6M |
-$83.9M |
+$9.75M |
NYT, PFE, NYCB, ORI, PTEN, BP |
13F-HR |
5/7/2014, 01:56 PM |
| Q4 2013 |
42 |
$581M |
|
|
|
NYT, PFE, NYCB, ORI, PTEN, HOLX |
13F-HR |
2/4/2014, 12:44 PM |